PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Clinical evidence
Administration of 96 mg/bw of agave fructans for 12 weeks significantly reduced body mass index (BMI) and decreased total body fat by 10% in obese volunteers [PMID:29417384].
Agave tequilana Weber blue variety fructans were evaluated for the improvement of symptoms in functional constipation as a prebiotic fiber supplementation [PMID:37389917].
In a murine model of systemic arterial hypertension (SAH), whole extracts and fractions of A. tequilana were evaluated for antihypertensive, anti-inflammatory, and antioxidant effects [PMID:35085011].
Evidence summary
PubMed sources
- 1.PMID: 7736598 (1995) — Tequila production. · Critical reviews in biotechnology
- 2.PMID: 36415865 (2022) — Conservation genomics of Agave tequilana Weber var. azul: low genetic differentiation and heterozygote excess in the tequila agave from Jalisco, Mexico. · PeerJ
- 3.PMID: 36079687 (2022) — Agave americana: Characteristics and Potential Breeding Priorities. · Plants (Basel, Switzerland)
- 4.PMID: 35085011 (2022) — Agave tequilana Counteracts Chronic Hypertension and Associated Vascular Damage. · Journal of medicinal food
- 5.PMID: 20657479 (2010) — Homoisoflavanones from Agave tequilana Weber. · Molecules (Basel, Switzerland)